New modalities: Innovations in hit identification

Synopsis

Innovations in hit identification (Hit ID) are transforming drug discovery by integrating AI-driven virtual screening, giga-scale library screening, and advanced biophysical techniques to accelerate lead generation. These approaches are not only enabling faster identification of high-quality hits but also expanding the druggable interactome to include targets once considered intractable.

The SCI “New modalities” series comprises focussed events addressing cutting-edge topics, and this year’s online symposium brings together world-class scientists at the forefront of hit identification for drug discovery.

---

Attendees

This event will be of interest to academic and industrial scientists engaged in hit identification for drug discovery, as well as scientists keen to know more about innovations in this field.

---

Confirmed speakers

Assay development and high-throughput screen for Poly A Polymerase Associated Domain enzyme inhibitors using an innovative mass spectrometry platform
Zachary Gurard-Levin, CEO and founder PeaPod Bio Inc

Next generation approaches to fragment-based drug discovery
Margherita Zanini, Astex

Title to be confirmed
Daniel Blair, St Jude Children’s Research Hospital

New modalities at Isomorphic labs
Albert Isidro-Llobet, Isomorphic Labs

---

Programme

The full programme will be confirmed in due course.

---

Contact

Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org

---

Fees

---

Booking Process/Deadlines

Booking terms and conditions

---

CPD Info

All delegates attending this meeting are able to claim CPD points.

---

Organising committee

Helen Horsley, UCB
Jason Tierney, Top Tier Consultancy
Kiri North, Vertex Pharmaceuticals
Nat Monck, Evotec
Rhydian Beddoe, CatSci

---